Orgenesis News and Resources

Orgenesis, a global biotech company has secured a $5 million equity line of credit from Williamsburg Venture Holdings. The deal provides $750,000 upon registration effectiveness, with a further $4.25 million accessible over two years. The funding will support Orgenesis’ initiatives